Inovio Pharmaceuticals HPV immunotherapy activates robust in vivo T cell responses in head and neck cancer patients

Inovio Pharmaceuticals, Inc. has announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck...